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Protein arginine deiminase type IV (PAD4) is responsible for the posttranslational conversion 
of peptidylarginine to peptidylcitrulline. Citrullinated protein is the autoantigen in rheumatoid 
arthritis, and therefore, PAD4 is currently a promising therapeutic target for the disease. 
Recently, we reported the importance of the furan ring in the structure of PAD4 inhibitors. In 
this study, the furan ring was incorporated into peptides to act as the “warhead” of the 
inhibitors for PAD4. IC50 studies showed that the furan-containing peptide-based inhibitors 
were able to inhibit PAD4 to a better extent than the furan-containing small molecules that 
were previously reported. The best peptide-based inhibitor inhibited PAD4 reversibly and 
competitively with an IC50 value of 243.2 ± 2.4 μm. NMR spectroscopy and NMR-restrained 
molecular dynamic simulations revealed that the peptide-based inhibitor had a random 
structure. Molecular docking studies showed that the peptide-based inhibitor entered the 
binding site and interacted with the essential amino acids involved in the catalytic activity. 
The peptide-based inhibitor could be further developed into a therapeutic drug for rheumatoid 
arthritis. 
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